Research Analysts Set Expectations for RDY FY2026 Earnings

Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Stock analysts at Zacks Research reduced their FY2026 earnings per share (EPS) estimates for Dr. Reddy's Laboratories in a report issued on Wednesday, February 12th. Zacks Research analyst R. Department now expects that the company will earn $0.79 per share for the year, down from their previous forecast of $0.80. The consensus estimate for Dr. Reddy's Laboratories' current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy's Laboratories' Q4 2026 earnings at $0.19 EPS and Q2 2027 earnings at $0.15 EPS.

Several other research analysts have also recently commented on the company. StockNews.com cut Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, December 6th. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th. Finally, Barclays cut their price target on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 6th.

Dr. Reddy's Laboratories Stock Down 0.3 %

Shares of NYSE:RDY traded down $0.04 during trading on Friday, hitting $13.57. The company's stock had a trading volume of 3,481,976 shares, compared to its average volume of 2,047,516. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy's Laboratories has a fifty-two week low of $13.36 and a fifty-two week high of $16.89. The stock's 50-day moving average price is $14.71 and its two-hundred day moving average price is $15.26. The company has a market capitalization of $11.32 billion, a PE ratio of 21.60 and a beta of 0.50.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%.

Institutional Trading of Dr. Reddy's Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Dr. Reddy's Laboratories by 100.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 16,511 shares of the company's stock valued at $261,000 after buying an additional 8,262 shares in the last quarter. Vident Advisory LLC raised its stake in Dr. Reddy's Laboratories by 535.5% during the fourth quarter. Vident Advisory LLC now owns 151,331 shares of the company's stock valued at $2,390,000 after buying an additional 127,518 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Dr. Reddy's Laboratories during the fourth quarter valued at approximately $1,007,000. Two Sigma Advisers LP raised its stake in Dr. Reddy's Laboratories by 254.8% during the fourth quarter. Two Sigma Advisers LP now owns 33,000 shares of the company's stock valued at $521,000 after buying an additional 23,700 shares in the last quarter. Finally, Thornburg Investment Management Inc. raised its stake in Dr. Reddy's Laboratories by 232.3% during the fourth quarter. Thornburg Investment Management Inc. now owns 69,751 shares of the company's stock valued at $1,101,000 after buying an additional 48,763 shares in the last quarter. Institutional investors and hedge funds own 3.85% of the company's stock.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.